CVS Health Corp
CVS
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
May 6, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
200.8% upsideUndervalued by 200.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $116.08 Billion |
|---|---|
| Enterprise Value | $184.89 Billion |
| Dividend Yield | $2.66 (2.92%) |
| Earnings per Share | $1.4 |
| Beta | 0.59 |
| Outstanding Shares | 1,273,000,000 |
Return
| Return on Equity | 3.79% |
|---|---|
| Return on Assets | 1.16% |
| Return on Invested Capital | 3.94% |
Valuation & Multiples
| P/E Ratio | 39.5 |
|---|---|
| PEG | 60.37 |
| Price to Sales | 0.29 |
| Price to Book Ratio | 1.52 |
| Enterprise Value to Revenue | 0.45 |
| Enterprise Value to EBIT | 28.16 |
| Enterprise Value to Net Income | 63 |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | 1.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6771▼ 17.13% |
|---|---|
| Total Calls | 19,423,022▼ 3.66% |
| Total Puts | 13,151,811▼ 23.10% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.75%▼ 2.49% |
|---|---|
| Total Invested | $78.91B▼ 12.58% |
| Investors Holding | 1,936▼ 87.00% |
ESG Score
No data
About CVS Health Corp
CEO: Larry Merlo Relevant Senate Committees
This non-partisan committee provides critical analysis and revenue estimates for all tax legislation. Its reports and expertise directly influence corporate tax structures, capital investment credits, and the overall tax burden on industries, thus having a direct and significant impact on CVS Health's financial performance and valuation.
This is one of the most powerful economic committees, controlling taxation, trade, and entitlement spending, including Medicare. It directly impacts CVS's profitability through corporate tax policy and significantly influences its revenue through Medicare pricing and reimbursement policies for Aetna and its PBM services.
This committee allocates discretionary federal spending. Its subcommittees determine the precise funding levels for federal healthcare programs (e.g., Medicare, Medicaid), which are critical revenue streams for Aetna and CVS's PBM and pharmacy operations. These funding decisions directly affect CVS Health's financial outlook and contract order books.
This committee directly regulates the FDA, NIH, and labor laws, and is central to health policy. It significantly impacts CVS's business through drug approval oversight (drugs sold in its pharmacies), labor regulations affecting its extensive workforce, and overall health legislation that shapes the health insurance (Aetna) and PBM sectors.
This committee oversees antitrust laws and intellectual property. Given CVS Health's significant size and market share in the pharmacy, PBM, and health insurance sectors (via Aetna), it is subject to potential antitrust scrutiny. Major mergers or acquisitions by CVS would also fall under this committee's purview, directly impacting its strategic growth and legal environment.
This committee investigates issues affecting older Americans, including drug pricing and long-term care quality. CVS Health serves a large population of seniors through its pharmacies and Aetna's Medicare Advantage plans. Hearings and recommendations on these issues create significant 'headline risk' and influence public pressure for regulatory changes directly impacting CVS's core business models.
This committee oversees the Department of Veterans Affairs, and its funding decisions directly impact government healthcare contractors. CVS Health, particularly through Aetna and its pharmacy services, likely provides services to veterans and contracts with the VA, making this committee's influence highly relevant to a segment of its revenue.